The Macular Degeneration Treatment Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Macular Degeneration Treatment Market:
https://www.thebusinessresearchcompany.com/report/macular-degeneration-treatment-global-market-report
According to The Business Research Company’s Macular Degeneration Treatment
Global Market Report 2024, The macular degeneration treatment market size has
grown rapidly in recent years. It will grow from $9.74 billion in 2023 to
$10.99 billion in 2024 at a compound annual growth rate (CAGR) of 12.8%. The
growth in the historic period can be attributed to aging population, lifestyle
changes, limited treatment options, rising awareness, healthcare infrastructure
development.
The macular degeneration treatment market size is expected to see rapid growth
in the next few years. It will grow to $16.99 billion in 2028 at a compound
annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be
attributed to advancements in research, increased healthcare expenditure,
rising incidence rates, personalized medicine approaches, global efforts for
vision health. Major trends in the forecast period include focus on
neuroprotection and regeneration therapies, expansion of telemedicine and
remote monitoring, personalized medicine approaches, investigation of stem cell
therapies, patient-focused initiatives for awareness and education.
The increasing burden of retinal disorders is expected to propel the growth of
the macular degeneration treatment market. Retinal disorders affect the vital
tissue and affect the way individuals process visual information, leading to
distorted or absent vision. According to the American Academy of Ophthalmology,
in 2050, an estimated 7.32 million people in the United States will have
primary open-angle glaucoma, a general term used to describe a group of eye
disorders, with the highest numbers among populations aged 70 to 79 years
(32%), women (50%), and Hispanics (50%). The largest demographic group is
Hispanic men. Therefore, the increasing burden of retinal disorders is driving
the growth of the macular degeneration treatment market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=5799&type=smp
The macular degeneration treatment market covered in this report is segmented –
1) By Stage of Disease: Early-Stage AMD, Intermediate AMD, Late-Stage AMD
2) By End User: Ambulatory Surgical Centers, Ophthalmic Clinics, Hospitals
3) By Route of Administration: Oral, Injectable, Other Route of Administration
4) By Types: Wet Macular Degeneration, Dry Macular Degeneration
Major companies in the macular degeneration treatment market are focused on
developing innovative solutions, such as avacincaptad pegol intravitreal
solution, for geographic atrophy, and maximizing their profits in the market.
Avacincaptad pegol intravitreal solution is a complement C5 inhibitor for
treating geographic atrophy secondary. For instance, in August 2023, Astellas
Pharma Inc., a Japan-based pharmaceutical company, received FDA approval for
IZERVAY, an avacincaptad pegol intravitreal solution for treating geographic
atrophy (GA) secondary to age-related macular degeneration (AMD). IZERVAY, a
complement C5 inhibitor, demonstrated a statistically significant reduction in
GA progression at the 12-month primary endpoint in two Phase 3 clinical trials,
with photoreceptor loss slowing as early as six months.
The macular degeneration treatment market report table of contents includes:
1. Executive Summary
2. Macular Degeneration
Treatment Market Characteristics
3. Macular Degeneration
Treatment Market Trends And Strategies
4. Macular Degeneration
Treatment Market - Macro Economic Scenario
5. Global Macular
Degeneration Treatment Market Size and Growth
.
32. Global Macular Degeneration Treatment Market Competitive Benchmarking
33. Global Macular
Degeneration Treatment Market Competitive Dashboard
34. Key Mergers And
Acquisitions In The Macular Degeneration Treatment Market
35. Macular Degeneration
Treatment Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model:
https://www.thebusinessresearchcompany.com/global-market-model
No comments:
Post a Comment